Keywords: UK, NICE, Bayer, Nexavar, Liver cancer,

UK’s NICE again rejects Bayer’s Nexavar for advanced liver cancer, but company can, and will, appeal

Article | 19 November 2009

Print This

Following a further appraisal, the UK’s National Institute for Health and Clinical Excellence (NICE) has again decided against recommending ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in